Phase I trial of YHI-1003

Phase I study of YHI-1003 monotherapy in patients with relapsed or refractory neuroblastoma

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222084

Enrollment

Registered

2013-05-17

Start date

2013-05-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

relapsed or refractory neuroblastoma

Interventions

investigational material(s) Generic name etc : YHI-1003 INN of investigational material : Perifosine Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigationa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients were previously diagnosed with neuroblastoma (2)Patients must have relapsed or refracted against the standard therary

Exclusion criteria

Exclusion criteria: (1)Patients were previously treated with Perifosine.

Design outcomes

Primary

Measure	Time frame
safety CTCAE v.4.0	—

Secondary

Measure	Time frame
efficacy and pharmacokinetic profile	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026